全文获取类型
收费全文 | 3026篇 |
免费 | 233篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 30篇 |
儿科学 | 97篇 |
妇产科学 | 79篇 |
基础医学 | 517篇 |
口腔科学 | 67篇 |
临床医学 | 245篇 |
内科学 | 630篇 |
皮肤病学 | 128篇 |
神经病学 | 399篇 |
特种医学 | 60篇 |
外科学 | 244篇 |
综合类 | 11篇 |
一般理论 | 1篇 |
预防医学 | 257篇 |
眼科学 | 37篇 |
药学 | 222篇 |
中国医学 | 4篇 |
肿瘤学 | 242篇 |
出版年
2024年 | 6篇 |
2023年 | 60篇 |
2022年 | 63篇 |
2021年 | 183篇 |
2020年 | 96篇 |
2019年 | 140篇 |
2018年 | 122篇 |
2017年 | 93篇 |
2016年 | 102篇 |
2015年 | 131篇 |
2014年 | 157篇 |
2013年 | 153篇 |
2012年 | 265篇 |
2011年 | 266篇 |
2010年 | 135篇 |
2009年 | 112篇 |
2008年 | 177篇 |
2007年 | 156篇 |
2006年 | 144篇 |
2005年 | 161篇 |
2004年 | 101篇 |
2003年 | 129篇 |
2002年 | 98篇 |
2001年 | 26篇 |
2000年 | 17篇 |
1999年 | 20篇 |
1998年 | 10篇 |
1997年 | 13篇 |
1996年 | 10篇 |
1995年 | 11篇 |
1994年 | 10篇 |
1993年 | 8篇 |
1992年 | 12篇 |
1991年 | 7篇 |
1990年 | 13篇 |
1989年 | 6篇 |
1988年 | 5篇 |
1987年 | 3篇 |
1985年 | 4篇 |
1982年 | 2篇 |
1980年 | 3篇 |
1979年 | 4篇 |
1978年 | 3篇 |
1975年 | 3篇 |
1974年 | 3篇 |
1973年 | 4篇 |
1971年 | 4篇 |
1931年 | 2篇 |
1930年 | 2篇 |
1929年 | 5篇 |
排序方式: 共有3270条查询结果,搜索用时 312 毫秒
101.
Bianca?Lauria-HornerEmail authorView authors OrcID profile Tara?Beaulieu Stephanie?Knaak Rivian?Weinerman Helen?Campbell Scott?Patten 《BMC family practice》2018,19(1):183
Background
Depression affects over 400 million people globally. The majority are seen in primary care. Barriers in providing adequate care are not solely related to physicians’ knowledge/skills deficits, but also time constraints, lack of confidence/avoidance, which need to be addressed in mental health-care redesign. We hypothesized that family physician (FP) training in the Adult Mental Health Practice Support Program (AMHPSP) would lead to greater improvements in patient depressive symptom ratings (a priori primary outcome) compared to treatment as usual.Methods
From October 2013 to May 2015, in a controlled trial 77 FP practices were stratified on the total number of physicians/practice as well as urban/rural setting, and randomized to the British Columbia AMHPSP?a multi-component contact-based training to enhance FPs’ comfort/skills in treating mild-moderate depression (intervention), or no training (control) by an investigator not operationally involved in the trial. FPs with a valid license to practice in NS were eligible. FPs from both groups were asked to identify 3–4 consecutive patients >?18?years old, diagnosis of depression, Patient Health Questionnaire (PHQ-9) score ≥ 10, able to read English, intact cognitive functioning. Exclusion criteria: antidepressants within 5?weeks and psychotherapy within 3?months of enrollment, and clinically judged urgent/emergent medical/psychiatric condition. Patients were assigned to the same arm as their physician. Thirty-six practices recruited patients (intervention n =?23; control n =?13). The study was prematurely terminated at 6?months of enrollment start-date due to concomitant primary health-care transformation by health-system leaders which resulted in increased in-office demands, and recruitment failure. We used the PHQ-9 to assess between-group differences at baseline, 1, 2, 3, and 6?months follow-up. Outcome collectors and assessors were blind to group assignment.Results
One hundred-and-twenty-nine patients (intervention n =?72; control n =?57) were analysed. A significant improvement in depression scores among intervention group patients emerged between 3 and 6?months, time by treatment interaction, likelihood ratio test (LR) chi2(3)?=?7.96, p =?.047.Conclusions
This novel skill-based program shows promise in translating increased FP comfort and skills managing depressed patients into improved patient clinical outcomes?even in absence of mental health specialists availability.Trial registration
#NCT01975948.102.
103.
Di Pino A Calabrò MP Gitto P Bianca I Oreto G 《Pacing and clinical electrophysiology : PACE》2007,30(2):280-282
We report the case of an infant affected by frequent episodes of loss of consciousness with the clinical features of pallid breath-holding attacks. Prolonged asystole, up to 26 seconds, was demonstrated by Holter monitoring. The patient was treated with permanent pacemaker implantation, followed by complete symptom resolution during a 26-month follow-up. 相似文献
104.
Eric Chung Michael Gillman John Tuckey Shane La Bianca Chris Love 《BJU international》2020,126(Z1):12-17
105.
106.
107.
Bianca Blanch Sallie-Anne Pearson Paul S Haber 《British journal of clinical pharmacology》2014,78(5):1159-1166
AimsTo report Australian population trends in subsidized prescribed opioid use, total costs to the Australian government to subsidize these medicines and opioid-related harms based on hospitalizations and accidental poisoning deaths.MethodsWe utilized three national aggregated data sources including dispensing claims from the Pharmaceutical Benefits Scheme, opioid-related hospitalizations from the National Hospital Morbidity Database and accidental poisoning deaths from the Australian Bureau of Statistics.ResultsBetween 1992 and 2012, opioid dispensing episodes increased 15-fold (500 000 to 7.5 million) and the corresponding cost to the Australian government increased 32-fold ($8.5 million to $271 million). Opioid-related harms also increased. Opioid-related hospitalizations increased from 605 to 1464 cases (1998–2009), outnumbering hospitalizations due to heroin poisonings since 2001. Deaths due to accidental poisoning (pharmaceutical opioids and illicit substances combined) increased from 151 to 266 (2002–2011), resulting in a rise in the death rate of 0.78 to 1.19 deaths/100 000 population over 10 years. Death rates increased 1.8 fold in males and 1.4 fold in females.ConclusionsThe striking increase in opioid use and related harms in Australia is consistent with trends observed in other jurisdictions. Further, there is no evidence to suggest these increases are plateauing. There is currently limited evidence in Australia about individual patterns of opioid use and the associated risk of adverse events. Further research should focus on these important issues so as to provide important evidence supporting effective change in policy and practice. 相似文献
108.
Bianca De Filippis Paola Nativio Alessia Fabbri Laura Ricceri Walter Adriani Enza Lacivita Marcello Leopoldo Francesca Passarelli Andrea Fuso Giovanni Laviola 《Neuropsychopharmacology》2014,39(11):2506-2518
Rett syndrome (RTT) is a rare neurodevelopmental disorder, characterized by severe behavioral and physiological symptoms. Mutations in the methyl CpG-binding protein 2 gene (MECP2) cause >95% of classic cases, and currently there is no cure for this devastating disorder. The serotonin receptor 7 (5-HT7R) is linked to neuro-physiological regulation of circadian rhythm, mood, cognition, and synaptic plasticity. We presently report that 5-HT7R density is consistently reduced in cortical and hippocampal brain areas of symptomatic MeCP2–308 male mice, a RTT model. Systemic repeated treatment with LP-211 (0.25 mg/kg once/day for 7 days), a brain-penetrant selective 5-HT7R agonist, was able to rescue RTT-related defective performance: anxiety-related profiles in a Light/Dark test, motor abilities in a Dowel test, the exploratory behavior in the Marble Burying test, as well as memory in the Novelty Preference task. In the brain of RTT mice, LP-211 also reversed the abnormal activation of PAK and cofilin (key regulators of actin cytoskeleton dynamics) and of the ribosomal protein (rp) S6, whose reduced activation in MECP2 mutant neurons by mTOR is responsible for the altered protein translational control. Present findings indicate that pharmacological targeting of 5-HT7R improves specific behavioral and molecular manifestations of RTT, thus representing a first step toward the validation of an innovative systemic treatment. Beyond RTT, the latter might be extended to other disorders associated with intellectual disability. 相似文献
109.
Bastian Grewe Carolin Vogt Theresa Horstktter Bettina Tippler Han Xiao Bianca Müller Klaus Überla Ralf Wagner Benedikt Asbach Jens Bohne 《Viruses》2021,13(6)
Alternative splicing and the expression of intron-containing mRNAs is one hallmark of HIV gene expression. To facilitate the otherwise hampered nuclear export of non-fully processed mRNAs, HIV encodes the Rev protein, which recognizes its intronic response element and fuels the HIV RNAs into the CRM-1-dependent nuclear protein export pathway. Both alternative splicing and Rev-dependency are regulated by the primary HIV RNA sequence. Here, we show that these processes are extremely sensitive to sequence alterations in the 5’coding region of the HIV genomic RNA. Increasing the GC content by insertion of either GFP or silent mutations activates a cryptic splice donor site in gag, entirely deregulates the viral splicing pattern, and lowers infectivity. Interestingly, an adaptation of the inserted GFP sequence toward an HIV-like nucleotide bias reversed these phenotypes completely. Of note, the adaptation yielded completely different primary sequences although encoding the same amino acids. Thus, the phenotypes solely depend on the nucleotide composition of the two GFP versions. This is a strong indication of an HIV-specific mRNP code in the 5′ gag region wherein the primary RNA sequence bias creates motifs for RNA-binding proteins and controls the fate of the HIV-RNA in terms of viral gene expression and infectivity. 相似文献
110.
In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets
下载免费PDF全文
![点击此处可从《Blood》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Goemans BF Zwaan CM Harlow A Loonen AH Gibson BE Hählen K Reinhardt D Creutzig U Heinrich MC Kaspers GJ 《Blood》2005,106(10):3532-3537
Although the prognosis of pediatric leukemias has improved considerably, many patients still have relapses. Tipifarnib, a farnesyl transferase inhibitor (FTI), was developed to target malignancies with activated RAS, including leukemia. We tested 52 pediatric acute myeloid leukemia (AML) and 36 pediatric acute lymphoblastic leukemia (ALL) samples for in vitro sensitivity to tipifarnib using a total cell-kill assay and compared these results to those obtained with normal bone marrow (N BM) samples (n = 25). AML samples were significantly more sensitive to tipifarnib compared to B-cell precursor ALL (BCP ALL) or N BM samples. Within AML, French-American-British (FAB) M5 samples were most sensitive to tipifarnib. T-cell ALL samples were significantly more sensitive than BCP ALL and N BM samples. In AML there was a marked correlation between tipifarnib resistance and daunorubicin or etoposide resistance, but not to cytarabine or 6-thioguanine. RAS mutations were present in 32% of AML and 18% of ALL samples, but there was no correlation between RAS mutational status and sensitivity to tipifarnib. Future studies are needed to identify biomarkers predictive of tipifarnib sensitivity. In addition, clinical studies, especially in T-cell ALL, seem warranted. 相似文献